擬10派39元 雲南白藥(000538.SZ)2020年度淨利潤升31.85%至55.16億元
格隆匯 3 月 26日丨雲南白藥(000538.SZ)發佈2020年年度報吿,實現營業收入327.43億元,同比增長10.38%;利潤總額68.01億元,同比增長43.90%;歸屬於上市公司股東的淨利潤55.16億元,同比增長31.85%;歸屬於上市公司股東的扣除非經常性損益的淨利潤28.99億元,同比增長26.63%;基本每股收益4.32元,擬每10股派發現金紅利39元(含税)。經營活動產生的現金流量淨額38.29億元,同比增長81.92%。
值得注意的是,健康品板塊,雲南白藥牙膏市場份額持續穩居全國第一,年末市場佔有率達到22.2%,“雲南白藥口腔健康醫學研究中心” 在京成立,未來將搭載現代化進程中一系列新技術、新手段,聚焦產學研深度融合,全方位提供口腔健康數字化智能護理及治療解決方案。報吿期內,雲南白藥集團上海科技有限公司、雲南白藥集團上海健康產品有限公司相繼成立,未來在AI皮膚檢測、全植物安全護膚、精準解決方案等方面將持續突破,探索醫美領域增長極。
健康品板塊,雲南白藥牙膏市場份額持續穩居全國第一,年末市場佔有率達到22.2%,“雲南白藥口腔健康醫學研究中心” 在京成立,未來將搭載現代化進程中一系列新技術、新手段,聚焦產學研深度融合,全方位提供口腔健康數字化智能護理及治療解決方案。報吿期內,雲南白藥集團上海科技有限公司、雲南白藥集團上海健康產品有限公司相繼成立,未來在AI皮膚檢測、全植物安全護膚、精準解決方案等方面將持續突破,探索醫美領域增長極。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.